Log in

OTCMKTS:RSPIRespirerx Pharmaceuticals Stock Price, Forecast & News

$0.0061
0.00 (0.00 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.01
Now: $0.01
$0.01
50-Day Range
$0.00
MA: $0.01
$0.02
52-Week Range
$0.00
Now: $0.01
$0.85
Volume16.86 million shs
Average Volume38.55 million shs
Market Capitalization$660,996.00
P/E RatioN/A
Dividend YieldN/A
Beta0.01
RespireRx Pharmaceuticals Inc. engages in the discovery and development of pharmaceuticals for the treatment of respiratory disorders. The company has two drug platforms comprising ampakines that act to enhance the actions of the excitatory neurotransmitter glutamate at AMPA glutamate receptors; and cannabinoids, primarily dronabinol, a synthetic derivative for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS. It develops various ampakines in oral and injectable form for the treatment of various breathing disorders. The company's lead ampakine, CX1739, which is in Phase II clinical studies for drug-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven respiratory disorders, neurobehavioral disorders, spinal cord injury, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was founded in 1987 and is based in Glen Rock, New Jersey.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RSPI
CUSIPN/A
Phone201-444-4947

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.79) per share

Profitability

Net Income$-2,120,000.00

Miscellaneous

Employees2
Market Cap$660,996.00
Next Earnings Date8/19/2020 (Estimated)
OptionableNot Optionable

Receive RSPI News and Ratings via Email

Sign-up to receive the latest news and ratings for RSPI and its competitors with MarketBeat's FREE daily newsletter.

Respirerx Pharmaceuticals (OTCMKTS:RSPI) Frequently Asked Questions

How has Respirerx Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Respirerx Pharmaceuticals' stock was trading at $0.0330 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RSPI stock has decreased by 81.5% and is now trading at $0.0061. View which stocks have been most impacted by Coronavirus.

When is Respirerx Pharmaceuticals' next earnings date?

Respirerx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for Respirerx Pharmaceuticals.

How were Respirerx Pharmaceuticals' earnings last quarter?

Respirerx Pharmaceuticals Inc (OTCMKTS:RSPI) announced its earnings results on Wednesday, May, 20th. The company reported ($0.14) EPS for the quarter. View Respirerx Pharmaceuticals' earnings history.

Has Respirerx Pharmaceuticals been receiving favorable news coverage?

News articles about RSPI stock have been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Respirerx Pharmaceuticals earned a coverage optimism score of -1.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Respirerx Pharmaceuticals.

Who are some of Respirerx Pharmaceuticals' key competitors?

What other stocks do shareholders of Respirerx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Respirerx Pharmaceuticals investors own include BlackRock (BLK), Ballard Power Systems (BLDP), Alibaba Group (BABA), Arrowhead Pharmaceuticals (ARWR), Aquestive Therapeutics (AQST), Appian (APPN), Arista Networks (ANET), Alexion Pharmaceuticals (ALXN), Allergan (AGN) and Adamis Pharmaceuticals (ADMP).

Who are Respirerx Pharmaceuticals' key executives?

Respirerx Pharmaceuticals' management team includes the following people:
  • Dr. Arnold S. Lippa, Exec. Chairman, Interim Pres, Interim CEO & Chief Scientific Officer (Age 72)
  • Dr. Jeff Eliot Margolis, Sr. VP, CFO, Treasurer, Sec. & Director (Age 63)
  • Mr. Richard D. Purcell, Sr. VP of R&D (Age 58)
  • Mr. Marc M. Radin, Controller
  • Dr. Arvid Carlsson M.D., Ph.D., Consultant (Age 96)

What is Respirerx Pharmaceuticals' stock symbol?

Respirerx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RSPI."

How do I buy shares of Respirerx Pharmaceuticals?

Shares of RSPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Respirerx Pharmaceuticals' stock price today?

One share of RSPI stock can currently be purchased for approximately $0.01.

How big of a company is Respirerx Pharmaceuticals?

Respirerx Pharmaceuticals has a market capitalization of $660,996.00. Respirerx Pharmaceuticals employs 2 workers across the globe.

What is Respirerx Pharmaceuticals' official website?

The official website for Respirerx Pharmaceuticals is www.respirerx.com.

How can I contact Respirerx Pharmaceuticals?

Respirerx Pharmaceuticals' mailing address is 126 VALLEY ROAD SUITE C, GLEN ROCK NJ, 07452. The company can be reached via phone at 201-444-4947 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.